Cytek Biosciences, Inc.

Cytek Biosciences Beats on EPS, Stock Up 2.56%

Cytek Biosciences reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 2.56%. However, there was no revenue reported and no guidance provided, leaving some uncertainty about future performance. Investors may view the EPS beat as a sign of improved cost management, but the lack of revenue details could raise questions about growth prospects.